Literature DB >> 25441763

MOR1 expression in gastric cancer: a biomarker associated with poor outcome.

Ya-sai Yao1, Ru-yong Yao, Li-kun Zhuang, Wei-wei Qi, Jing Lv, Fei Zhou, Wen-sheng Qiu, Lu Yue.   

Abstract

BACKGROUND: At present, the expression of MOR1 and its function in gastric cancer remains unclear with evidence suggesting that it is to be involved in tumor progression and metastasis. The study was to assess the clinicopathologic relevance and prognostic value of MOR1 expression in gastric cancer.
METHODS: Real-time quantitative RT-PCR and immunohistochemical staining were used to detect MOR1 expression in primary gastric cancerous surgical specimens and adjacent nontumorous tissues.
RESULTS: High MOR1 expression was detected in cancerous tumor compared with their adjacent nontumorous tissues. In addition, the chi-square test revealed that high MOR1 expression was significantly correlated with depth of invasion (p = 0.006), lymph node metastasis (p = 0.001), distant metastasis (p = 0.017), and TNM staging (p = 0.027). Moreover, Kaplan-Meier analysis revealed a significant association between MOR1 expression and overall survival. High expression of MOR1 was identified as an independent and significant predictor gene of reduced postoperative survival.
CONCLUSION: We conclude that MOR1 expression may be a useful biomarker for better prediction of the clinical outcome and management of gastric cancer patients.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  MOR1; gastric cancer; metastasis; prognosis

Mesh:

Substances:

Year:  2014        PMID: 25441763      PMCID: PMC5350983          DOI: 10.1111/cts.12246

Source DB:  PubMed          Journal:  Clin Transl Sci        ISSN: 1752-8054            Impact factor:   4.689


  35 in total

Review 1.  Endogenous opiates and behavior: 2003.

Authors:  Richard J Bodnar; Gad E Klein
Journal:  Peptides       Date:  2004-12       Impact factor: 3.750

2.  Effects of anesthetics on cancer recurrence.

Authors:  Jonathan Moss; Robert J Israel
Journal:  J Clin Oncol       Date:  2009-08-03       Impact factor: 44.544

3.  Efficacy and safety of fentanyl pectin nasal spray compared with immediate-release morphine sulfate tablets in the treatment of breakthrough cancer pain: a multicenter, randomized, controlled, double-blind, double-dummy multiple-crossover study.

Authors:  Marie Fallon; Carlo Reale; Andrew Davies; A Eberhard Lux; Kirushna Kumar; Andrzej Stachowiak; Rafael Galvez
Journal:  J Support Oncol       Date:  2011 Nov-Dec

4.  Synergistic effects of methylnaltrexone with 5-fluorouracil and bevacizumab on inhibition of vascular endothelial growth factor-induced angiogenesis.

Authors:  Patrick A Singleton; Joe G N Garcia; Jonathan Moss
Journal:  Mol Cancer Ther       Date:  2008-06       Impact factor: 6.261

5.  Methylnaltrexone potentiates the anti-angiogenic effects of mTOR inhibitors.

Authors:  Patrick A Singleton; Nurbek Mambetsariev; Frances E Lennon; Biji Mathew; Jessica H Siegler; Liliana Moreno-Vinasco; Ravi Salgia; Jonathan Moss; Joe Gn Garcia
Journal:  J Angiogenes Res       Date:  2010-02-19

Review 6.  Opioid peptides in cancer.

Authors:  Jakub Fichna; Anna Janecka
Journal:  Cancer Metastasis Rev       Date:  2004 Aug-Dec       Impact factor: 9.264

7.  Mu, delta, and kappa opiate receptor binding of Tyr-MIF-1 and of Tyr-W-MIF-1, its active fragments, and two potent analogs.

Authors:  J E Zadina; A J Kastin; L J Ge; L Hackler
Journal:  Life Sci       Date:  1994       Impact factor: 5.037

8.  Morphine stimulates angiogenesis by activating proangiogenic and survival-promoting signaling and promotes breast tumor growth.

Authors:  Kalpna Gupta; Smita Kshirsagar; Liming Chang; Robert Schwartz; Ping-Y Law; Doug Yee; Robert P Hebbel
Journal:  Cancer Res       Date:  2002-08-01       Impact factor: 12.701

Review 9.  The role of morphine in regulation of cancer cell growth.

Authors:  Katarzyna Gach; Anna Wyrębska; Jakub Fichna; Anna Janecka
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-07-29       Impact factor: 3.000

10.  The prognostic value of tumor-infiltrating neutrophils in gastric adenocarcinoma after resection.

Authors:  Jing-jing Zhao; Ke Pan; Wei Wang; Ju-gao Chen; Yan-heng Wu; Lin Lv; Jian-jun Li; Yi-bing Chen; Dan-dan Wang; Qiu-zhong Pan; Xiao-dong Li; Jian-chuan Xia
Journal:  PLoS One       Date:  2012-03-19       Impact factor: 3.240

View more
  11 in total

Review 1.  Chronic Cancer Pain: Opioids within Tumor Microenvironment Affect Neuroinflammation, Tumor and Pain Evolution.

Authors:  Angela Santoni; Matteo Santoni; Edoardo Arcuri
Journal:  Cancers (Basel)       Date:  2022-04-30       Impact factor: 6.575

Review 2.  Opioids and Cancer Mortality.

Authors:  Jaya Amaram-Davila; Mellar Davis; Akhila Reddy
Journal:  Curr Treat Options Oncol       Date:  2020-02-20

3.  Methadone as a "Tumor Theralgesic" against Cancer.

Authors:  Marta Michalska; Arndt Katzenwadel; Philipp Wolf
Journal:  Front Pharmacol       Date:  2017-10-31       Impact factor: 5.810

4.  Pain, opioid therapy, and survival: a needed discussion.

Authors:  Diane M Novy; David V Nelson; Dhanalakshmi Koyyalagunta; Juan P Cata; Pankaj Gupta; Kalpna Gupta
Journal:  Pain       Date:  2020-03       Impact factor: 6.961

Review 5.  Less Well-Known Consequences of the Long-Term Use of Opioid Analgesics: A Comprehensive Literature Review.

Authors:  Aleksandra Kotlińska-Lemieszek; Zbigniew Żylicz
Journal:  Drug Des Devel Ther       Date:  2022-01-18       Impact factor: 4.162

6.  Subcutaneous Methylnaltrexone for Treatment of Opioid-Induced Constipation in Cancer versus Noncancer Patients: An Analysis of Efficacy and Safety Variables from Two Studies.

Authors:  Bruce H Chamberlain; Michelle Rhiner; Neal E Slatkin; Nancy Stambler; Robert J Israel
Journal:  J Pain Res       Date:  2021-09-01       Impact factor: 3.133

7.  Solid Tumor Opioid Receptor Expression and Oncologic Outcomes: Analysis of the Cancer Genome Atlas and Genotype Tissue Expression Project.

Authors:  Amparo Belltall; Sheila Zúñiga-Trejos; Iris Garrido-Cano; Pilar Eroles; Maria Pilar Argente-Navarro; Donal J Buggy; Oscar Díaz-Cambronero; Guido Mazzinari
Journal:  Front Oncol       Date:  2022-03-10       Impact factor: 6.244

8.  Opioid Receptor Expression in Colorectal Cancer: A Nested Matched Case-Control Study.

Authors:  Amparo Belltall; Guido Mazzinari; Iris Garrido-Cano; Francisco Giner; Anabel Marqués Marí; Pilar Eroles; María Pilar Argente-Navarro; Juan Pablo Cata; Oscar Diaz-Cambronero
Journal:  Front Oncol       Date:  2022-04-06       Impact factor: 5.738

9.  The influence of brain metastases on the central nervous system effects of methylnaltrexone: a post hoc analysis of 3 randomized, double-blind studies.

Authors:  Darren M Brenner; Neal E Slatkin; Nancy Stambler; Robert J Israel; Paul H Coluzzi
Journal:  Support Care Cancer       Date:  2021-02-25       Impact factor: 3.603

10.  The effect of anesthetic technique on µ-opioid receptor expression and immune cell infiltration in breast cancer.

Authors:  Kirk J Levins; S Prendeville; S Conlon; D J Buggy
Journal:  J Anesth       Date:  2018-09-18       Impact factor: 2.078

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.